I am writing to express my appreciation for the ongoing discourse regarding treatment options for Castleman [1,2] disease with Siltuximab. The evidence supporting Siltuximab’s efficacy is compelling, demonstrating substantial improvements in both clinical symptoms and quality of life for patients with multicentric Castleman disease.